Victims of the pregnancy drug diethylstilbestrol (DES) are calling for a national inquiry into its devastating effects. This campaign, spearheaded by a group of over 300 individuals, seeks recognition for the harm caused by the drug, which is linked to cancer and other serious health complications.
Cancer-Linked Pregnancy Drug Overview
Diethylstilbestrol, a synthetic estrogen, was prescribed to millions of pregnant women worldwide from the 1940s until the late 1970s. Initially recommended to prevent miscarriage and other pregnancy complications, DES was linked to various cancers, including clear cell adenocarcinoma of the cervix and vagina, in studies by the early 1970s.
A Call for Action
- Over 300,000 women in the UK received DES before it was banned.
- Campaigners liken the DES scandal to the infamous Thalidomide tragedy.
- Victims have suffered for decades, often facing significant medical challenges without adequate support.
One of the prominent figures in this campaign is Susie Martin. She attributes her ongoing health issues to the drug prescribed to her mother, Jennifer Bradley, during pregnancy. Martin has undergone between 20 and 30 surgeries, requiring lifelong screenings for various cancers.
Personal Stories of Suffering
Jennifer Bradley was prescribed DES in 1968 and again in 1970 during her pregnancies. After watching a documentary on DES-related health risks in the 1970s, she consulted her doctor, but her concerns were dismissed. “He assured me it was safe,” she recalls, reflecting on her feelings of guilt as her daughter later faced health complications linked to the drug.
The Aftermath of DES
Thousands of women and their descendants are affected by the fallout of DES. Many have developed reproductive health issues and face increased cancer risks. Despite existing compensation schemes in the US and the Netherlands, no such measures are available in the UK.
Regulatory Oversight and Apologies
The Medicines and Healthcare products Regulatory Agency (MHRA) acknowledged the oversight in communicating the risks associated with DES. In 1973, UK doctors were informed of a US study regarding vaginal adenocarcinoma but did not receive clear warnings against prescribing DES to pregnant women.
Recent statements from the Department of Health and Social Care express sympathy for those affected and highlight ongoing efforts to address the legacy of DES. The Secretary of State is reportedly looking into enhancing support for those impacted by this historical medical failure.
Advocacy for Justice
The newly formed DES Justice UK group, following media investigations, aims to advocate for victims and their families. It stresses the urgent need for a public inquiry into the long-term effects of DES and the accountability of pharmaceutical companies involved in its production.
As the campaign gains momentum, advocates stress that victims deserve answers and recognition for their suffering. It is crucial that the government acts to ensure justice and support for those grievously affected by this scandal.
